Acute suicidality after commencing atomoxetine - PubMed (original) (raw)
Case Reports
Acute suicidality after commencing atomoxetine
Georgia Armat Paxton et al. J Paediatr Child Health. 2008 Oct.
Abstract
An 11 year old boy developed acute agitation and suicidal ideation after commencing atomoxetine shortly after it was approved for use in Australia. The clinical features were similar to reactions described in response to selective serotonin reuptake inhibitors. The case highlights the importance of close monitoring when starting newly registered medications. An increased risk of suicidal thinking was subsequently identified for this drug leading to a Food and Drug Administration alert and a boxed warning in September 2005, however there are still no other published case reports of acute suicidality.
Comment in
- Combining atomoxetine with carbamazepine or neuroleptics reduces adverse side effects.
Niederhofer H. Niederhofer H. J Paediatr Child Health. 2010 Jan;46(1-2):66. doi: 10.1111/j.1440-1754.2009.01665.x. J Paediatr Child Health. 2010. PMID: 20412195 No abstract available.
Similar articles
- Atomoxetine use during a period of FDA actions.
Du DT, Zhou EH, Goldsmith J, Nardinelli C, Hammad TA. Du DT, et al. Med Care. 2012 Nov;50(11):987-92. doi: 10.1097/MLR.0b013e31826c86f1. Med Care. 2012. PMID: 23047788 - An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. Takahashi M, et al. Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x. Psychiatry Clin Neurosci. 2011. PMID: 21265936 Clinical Trial. - [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E, Gastpar M. Davids E, et al. Fortschr Neurol Psychiatr. 2004 Oct;72(10):586-91. doi: 10.1055/s-2004-830049. Fortschr Neurol Psychiatr. 2004. PMID: 15472782 German. - Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Eiland LS, Guest AL. Eiland LS, et al. Ann Pharmacother. 2004 Jan;38(1):86-90. doi: 10.1345/aph.1D144. Ann Pharmacother. 2004. PMID: 14742801 Review. - Atomoxetine in the treatment of attention deficit hyperactivity disorder.
Kratochvil CJ, Vaughan BS, Daughton JM, Mayfield-Jorgensen ML, Burke WJ. Kratochvil CJ, et al. Expert Rev Neurother. 2004 Jul;4(4):601-11. doi: 10.1586/14737175.4.4.601. Expert Rev Neurother. 2004. PMID: 15853579 Review.
Cited by
- The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill DR, Kryzhanovskaya LA, Savill NC. Reed VA, et al. CNS Drugs. 2016 Jul;30(7):603-28. doi: 10.1007/s40263-016-0349-0. CNS Drugs. 2016. PMID: 27290715 Review. - Advances in understanding and treating ADHD.
Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Antshel KM, et al. BMC Med. 2011 Jun 10;9:72. doi: 10.1186/1741-7015-9-72. BMC Med. 2011. PMID: 21658285 Free PMC article. Review. - Systematic Review of Suicidal Behaviors Related to Methylphenidate and Atomoxetine in Patients With Attention Deficit Hyperactivity Disorder.
Kim JH, Park S, Lee YJ. Kim JH, et al. Soa Chongsonyon Chongsin Uihak. 2023 Apr 1;34(2):125-132. doi: 10.5765/jkacap.220040. Soa Chongsonyon Chongsin Uihak. 2023. PMID: 37035791 Free PMC article. Review. - Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder.
Kohn MR, Tsang TW, Clarke SD. Kohn MR, et al. Clin Med Insights Pediatr. 2012 Nov 5;6:95-162. doi: 10.4137/CMPed.S7868. Print 2012. Clin Med Insights Pediatr. 2012. PMID: 23641171 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical